Sufugolix
Grundinformationen
- CAS
308831-61-0- Standard-SMILES
CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1- InChIKey
UCQSBGOFELXYIN-UHFFFAOYSA-N- Summenformel
- C36H31F2N5O4S
- Durchschnittliche Molmasse
- 667,7 g/mol
- Monoisotopische Masse
- 667,20648191
Namen und Bezeichner
- Bevorzugter Name
- Sufugolix
- IUPAC
- 1-[4-[5-[[benzyl(methyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- Englischer Name
- SUFUGOLIX
- Summenformel
- C36H31F2N5O4S
- Molmasse
- 667.72
Namen und Synonyme
Sufugolix308831-61-0TAK-013Sufugolix [INN:BAN]TAK 01356S17Z6X9MSUFUGOLIX [INN]DTXSID401848931-[4-(5-{[BENZYL(METHYL)AMINO]METHYL}-1-[(2,6-DIFLUOROPHENYL)METHYL]-2,4-DIOXO-3-PHENYL-1H,2H,3H,4H-THIENO[2,3-D]PYRIMIDIN-6-YL)PHENYL]-3-METHOXYUREA1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(methyl-(phenylmethyl)amino)methyl]-2,4-dioxo-3-phenylthieno[4,5-e]pyrimidin-6-yl]phenyl]-3-methoxyurea5-((BENZYL(METHYL)AMINO)METHYL)-1-(2,6-DIFLUOROBENZYL)-6-(4-(3-METHOXYUREIDO)PHENYL)-3-PHENYLTHIENO(2,3-D)PYRIMIDINE-2,4(1H,3H)-DIONE5-(N-Benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-(4-(3-methoxyureido)phenyl)-3-phenylthieno(2,3-d)pyrimidine-2,4(1H,3H)-dione
Weitere Namen anzeigen
TAK013tak-013, >98%TAK013SUFUGOLIX, >98%Sufugolix(TAK-013)Sufugolix, 10 mM in DMSOTAK 013,Inhibitor,Sufugolix,inhibit,TAK013N-(4-(5-((benzyl(methyl)amino)methyl)-1-(2,6-difluorobenzyl)-1,2,3,4-tetrahydro-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 6,1
- Polarare Oberfläche (TPSA)
- 122 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 10
- Schwere Atome
- 48
- Formalladung
- 0
- Komplexität
- 1.090
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
LogP4.04
Physikochemische Eigenschaften
- Dichte
- 1.383 · 1.383±0.06 g/cm3(Predicted)
- storage temp.
- -20 °C,unstable · Store at -20°C,unstable in solution, ready to use.
- Löslichkeit
- 5 mg/mL; · DMF: 5mg/mL; DMF:PBS (pH 7.2) (1:2): 0.3mg/mL; DMSO: 3mg/mL
- Aggregatzustand
- A solid
- pka
- 13.2 · 13.20±0.70(Predicted)
- Farbe
- Light yellow to yellow
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- Alarmwort
- Warnung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315
Chemie und Industrie
Pharmakologische Informationen
Mechanism of Action
Endometriosis is a painful, fertility threatening condition that is a result of tissue similar to that found in the womb lining growing elsewhere in the pelvis. The condition is sex hormone dependent, with gonadotropin releasing hormone (GnRH), a hypothalamic decapeptide amide that plays an important part in the regulation of reproductive processes, being implicated. TAK-013 behaves as an insurmountable antagonist at the human receptor (hGnRHR). It suppresses gonadotropin release.
Anwendungen
BeschreibungSufugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist (IC50 = 0.1 nM). Sufugolix inhibits GnRH-induced arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) release in CHO cells expressing human recombinant or monkey recombinant GnRH (IC50s = 0.1 and 10 nM, respectively), but not the rat GnRH receptor. It inhibits luteinizing hormone (LH) release stimulated by GnRH in monkey pituitary cells ex vivo (IC50 = 36 nM). Sufugolix (10 and 30 mg/kg) reduces increases in plasma LH following castration in male cynomolgus monkeys and lowers serum LH, estradiol, and progesterone levels in female cynomolgus monkeys when administered at a dose of 90 mg/kg.
Anbieter48 Anbieter
沈阳中申泽康生物医学技术研究有限公司024-88590548 18698872706 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
武汉敬康恩生物医药科技有限公司13720134139 086-15871494362 13720134139 · [email protected]
Nantong HI-FUTURE Biology Co., Ltd.+86-18051384581 · [email protected]
欧利希（湖北）医药科技有限公司17316404525 17316404525 · [email protected]
Zugehörige Reaktionen
10
Notizen zur Verbindung
Wird geladen…